Florence Séjourné

CEO, AUROBAC THERAPEUTICS & Board Member and Founder, BEAM Alliance

Florence Séjourné is the CEO of AUROBAC THERAPEUTICS, a biopharmaceutical company she has led since its inception to address severe hospital infections amid the rise of antimicrobial resistance (AMR), through patient- and pathogen-targeted R&D associated to innovative diagnostic strategies. She is also the founder and current Board member of the BEAM Alliance, representing over 70 European biotech companies advocating for policies and incentives to advance antimicrobial innovation. A seasoned biotech leader, she previously served as CEO of Da Volterra, guiding it from early scientific concepts to late-stage clinical development in AMR, and co-founded Genfit (GNFT), focused on rare and life-threatening liver diseases. She holds engineering and pharmaceutical sciences degrees from Mines Paris – PSL and the University of Illinois at Chicago.